U.S. Markets closed

Prestige Consumer (PBH) Stock Down Despite Q1 Earnings Beat

Zacks Equity Research

Prestige Consumer Healthcare Inc. PBH came out with first-quarter fiscal 2020 results, wherein both top and bottom lines surpassed the Zacks Consensus Estimate. This marked the second straight quarter of positive earnings and sales surprise. Results were driven by robust performance of leading brands and enhanced gross margin.

However, earnings and sales declined year over year. Markedly, shares of the company declined close to 3% during the trading session on Aug 1.

Q1 Details

The company posted adjusted earnings of 65 cents per share, which outpaced the Zacks Consensus Estimate by a penny. This marked its sixth consecutive quarter of earnings beat. However, quarterly earnings declined 4.4% year over year.

Total revenues of $232.2 million exceeded the Zacks Consensus Estimate of $231.3 million. However, the top line dropped 8.6% year over year, while organic revenues remained flat. Revenues were driven by robust consumption trends at core categories and solid international unit offset by inventory reductions. We note that organic revenues don’t include the impact of the sale of Household Cleaning segment and foreign currency movements.

Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise

 

Prestige Consumer Healthcare Inc. Price, Consensus and EPS Surprise

Prestige Consumer Healthcare Inc. price-consensus-eps-surprise-chart | Prestige Consumer Healthcare Inc. Quote

 

Gross profit came in at $134.1 million, reflecting a decline of 4.8% from the prior-year quarter’s figure. However, gross margin expanded 230 basis points (bps) to 57.7% in the fiscal first quarter, primarily driven by the divestiture of the Household Cleaning segment.

Adjusted EBITDA was $78.1 million, down 5.1% year over year, owing to the Household Cleaning segment divestiture. Adjusted EBITDA margin expanded 130 bps to 33.7%.

Segment Performance

Following the divestiture of the Household Cleaning segment on Jul 2, 2018, Prestige Consumer is currently operating two segments — the North American OTC Healthcare and the International OTC Healthcare.

Revenues in the North American OTC Healthcare segment were $210.8 million, down 1.9% year over year. This is accountable to inventory reductions, and adverse foreign currency of $0.5 million – which was somewhat compensated by increased consumption at core categories.

Revenues in the International OTC Healthcare segment totaled $21.4 million, up 10.3% from the year-ago quarter. The rise was attributable to increased consumption at core categories, and timing of shipments and distributor orders, which were partly negated by currency headwinds to the tune of $1 million.

Financial Updates

The company exited the quarter under review with cash and cash equivalents of $29 million, net long-term debt of $1,779.4 million and total shareholders’ equity of $1,101.6 million. Also, the company lowered its debt by $20 million in the first quarter and repurchased shares worth roughly $30 million. Net cash provided by operating activities in the reported quarter was $52.8 million.

As on Jun 30, 2019, the company’s net debt position was about $1.8 billion.

Outlook

Management reaffirmed fiscal 2020 guidance. The company anticipates growth in product categories to be offset by lower retail inventory and consolidation plans. Prestige Consumer is on track with its three core strategies, and also making efforts to maintain a strong financial profile and maximize capital allocation. Proceeds from capital allocation efforts will enable the company to reduce debt to some extent and repurchase shares.

In fiscal 2020, the company continues to expect revenues of $951-$961 million and organic growth to remain nearly flat. Adjusted earnings per share are still envisioned in a band of $2.76-$2.83. In this regard, it had earlier highlighted that adjusted earnings will be more weighted in the second half of fiscal 2020 due to increased A&P and G&A spending in the first half.  

Free cash flow is forecasted to be $200 million or more in fiscal 2020.

Price Performance

The Zacks Rank #2 (Buy) stock has rallied 19% in the past six months, against the industry’s decline of 9.1%.

3 Stocks to Watch

Skechers U.S.A., Inc. SKX has a long-term earnings growth rate of 15%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

lululemon athletica inc. LULU has a long-term earnings growth rate of 18.4% and a Zacks Rank #2.

Church & Dwight Co., Inc. CHD has a long-term earnings growth rate of 8.6% and a Zacks Rank #2.    

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>